Taurine Supplementation in Long COVID
A legfontosabb adatok
- Hol
- Edmonton, Montreal, Sherbrooke, Toronto és Vancouver (Kanada)Mind a 5 helyszín megnézése
- Fázis
- 2/3. fázis
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek a hosszú COVID tünetei az akut betegség után több mint 3 hónappal is fennállnak. A tauringyógyszert placebóval hasonlítja össze.
- Életkor
- 18 éves vagy idősebb
- Nem
- Bármely nemű személy részt vehet
- A betegség stádiuma
- Hosszú COVID: a COVID-19 kezdete után több mint 3 hónappal is fennálló tünetek, amelyek legalább 2 hónapja tartanak, és a randomizáláskor is jelen vannak. A COVID-19-et a randomizálás előtt legalább 3 hónappal teszt igazolta, vagy a vizsgálóhely kutatója 2019. október 15. után lezajlott akut betegségként feltételezte.
- Korábbi kezelés
- A tünetek kezelésének legalább 4 hete stabilnak kell lennie. A fáradtságra vagy gondolkodási zavarra szedett gyógyszereket (sildenafil, modafinil, armodafinil, guanfacin, N-acetil-cisztein, ADHD-stimulánsok) 4 hete le kell állítani.
A részvétel fő kizáró okai
- A COVID-19 miatt gépi lélegeztetésre vagy ECMO-ra szorult
- Jelenlegi szervelégtelenség, szervátültetés, vagy jelenleg akut ellátást nyújtó kórházban fekszik
- Terhes vagy szoptat
- Másik beavatkozásos vizsgálatban vagy a hosszú COVID idegrendszeri tüneteit célzó másik vizsgálatban részt vesz
- A vizsgált kezelés ellenjavallt, vagy már kapja a vizsgált kezelést
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Kanada
- University of Alberta Hospital/Kaye Edmonton ClinicEdmonton, KanadaContact: Grace Lam, MDRésztvevőt keres
- Institut de Recherches Cliniques de MontrealMontreal, KanadaContact: Liana Falcone, MDRésztvevőt keres
- Centre integre universitaire de sante et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de SherbrookeSherbrooke, KanadaContact: Alain Piché, MDRésztvevőt keres
- University Health NetworkToronto, KanadaContact: Angela Cheung, MDRésztvevőt keres
- BC Women's HospitalVancouver, KanadaContact: Karen Tran, MDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- University of Alberta
- Azonosító
- NCT06721949
- A regiszteradat frissítve
- 2026. szeptember 18.
- Eredeti leírás
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.A teljes eredeti leírásKevesebb
Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.
Bevonási feltételek: Age ≥18 years; Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to randomization; If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks); Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms; Lingering symptoms from COVID-19 present at the time of randomization; Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator (refer to Section 5 Contraception of the Master Protocol, and Section 13.1.2 of this protocol); Must be able to provide informed consent and both willing and able to comply with study requirements; Medications prescribed for treating fatigue or cognition have been discontinued for four weeks prior to enrolment and randomization. These include sildenafil, modafinil (Provigil), or armodafinil (Nuvigil), guanfacine, N-acetyl cysteine, and stimulant medications used for attention-deficit hyperactivity disorder (ADHD).
Kizáró feltételek: Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19; Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital; Contraindications to the study intervention; Currently already on study intervention(s); Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted); Currently pregnant or breastfeeding; The participant is currently enrolled in another clinical trial to treat neurocognitive symptoms in LC.